On September 29, 2022 Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies and, the Translational Research Unit (TRU) platform of University of Bern, that develops novel workflows for tissue microarray (ngTMA) construction, reported a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and the use of next generation TMAs to unlock spatial analysis in scientific research and improve the quality of TMAs integrated in clinical and translational research (Press release, Ultivue, SEP 29, 2022, View Source [SID1234621564]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics. Its proprietary InSituPlex technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
ngTMA supports research collaborators with an interdisciplinary approach to studying tumor biology and disease states. Services include scientific consulting and TMA design, digital slide annotation, automated tissue punching and documentation for quality control. The ngTMA platform is embedded in an innovative research framework and as part of the Translational Research Unit (TRU), Institute of Pathology, University of Bern, with expertise in tissue-related technologies.
"We are thrilled to be partnering with ngTMA to jointly empower biopharma customers with tissue multiplex services. In addition, our scientific collaboration will investigate the relevance of the tumor microenvironment by characterizing clinically well-annotated cohorts using Ultivue reagents at ngTMA," said Florian Leiss, Ph.D. Vice President Product Strategy & Corporate Development at Ultivue.
"We are very excited to join forces with the Ultivue team and have their reagents in our pipeline in order to support translational research of our collaborators," Said Paulina Brönnimann, PhD, Head of Translational Research Unit.